养胃颗粒联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎脾虚气滞证临床研究  

Clinical Study on Yangwei Granules Combined with Rabeprazole Sodium EntericCoated Tablets for Chronic Gastritis Complicated with Reflux Esophagitis of Spleen Deficiency and Qi Stagnation Syndrome

作　　者：王艳娇 朱雅碧[1] WANG Yanjiao;ZHU Yabi

机构地区：[1]丽水市人民医院消化内科,浙江丽水323000

出　　处：《新中医》2023年第6期59-63,共5页New Chinese Medicine

基　　金：浙江省医学会临床科研基金项目(2020ZYC-A99)。

摘　　要：目的:观察养胃颗粒联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎脾虚气滞证的临床疗效。方法:选取86例慢性胃炎伴反流性食管炎脾虚气滞证患者,以简单随机化法分为治疗组与对照组各43例。2组均给予饮食指导,在此基础上,对照组给予雷贝拉唑钠肠溶片治疗,治疗组在对照组基础上给予养胃颗粒治疗,2组均治疗2周。比较2组临床疗效、不良反应发生率,以及治疗前后中医证候评分、胃肠激素水平及炎症因子水平。结果:治疗后,治疗组临床疗效总有效率95.35%,高于对照组81.40%(P<0.05)。治疗后,2组胃脘胀痛或胀满、反酸、烧心、神疲乏力、面色萎黄、食欲不振评分均较治疗前降低(P<0.05),治疗组上述6项中医证候评分均低于对照组(P<0.05);2组血浆胃动素(MLT)、血清胃泌素(GAS)水平均较治疗前升高(P<0.05),血清白细胞介素-6 (IL-6)、白细胞介素-17 (IL-17)水平均较治疗前降低(P<0.05);治疗组血浆MLT、血清GAS水平均高于对照组(P<0.05),血清IL-6、IL-17水平均低于对照组(P<0.05)。治疗期间,治疗组不良反应发生率4.65%,与对照组9.30%比较,差异无统计学意义(P>0.05)。结论:养胃颗粒联合雷贝拉唑钠肠溶片治疗慢性胃炎伴反流性食管炎脾虚气滞证疗效确切,可有效缓解患者的临床症状,提高胃动力,抑制炎症反应,安全性好。Objective:To observe the clinical effect of the therapy of Yangwei Granules combined with Rabeprazole Sodium Enteric-Coated Tablets on chronic gastritis complicated with reflux esophagitis of spleen deficiency and qi stagnation syndrome. Methods: A total of 86 patients with chronic gastritis complicated with reflux esophagitis of spleen deficiency and qi stagnation syndrome were selected and divided into the treatment group and the control group by simple randomized method, with 43 cases in each group. Both groups were given dietary guidance. On this basis, the control group was additionally treated with Rabeprazole Sodium Enteric-Coated Tablets,and the treatment group was additionally treated with Yangwei Granules based on the treatment of the control group. Both groups were treated for 2 weeks.The clinical effects,incidence of adverse reactions and the traditional Chinese medicine(TCM) syndrome scores, gastrointestinal hormone levels and inflammatory factors levels before and after treatment were compared between the two groups. Results:After treatment,the total effective rate was 95.35% in the treatment group,higher than that of 81.40% in the control group(P<0.05). After treatment,the scores of epigastric distension pain or fullness,acid reflux,heartburn,mental fatigue and lack of strength,sallowyellow complexion and loss of appetite in the two groups were all decreased when compared with those before treatment(P<0.05),and the above 6 TCM syndrome scores in the treatment group were lower than those in the control group(P<0.05). After treatment,the levels of plasma motilin(MLT) and serum gastrin(GAS) in the two groups were increased when compared with those before treatment(P<0.05),and the levels of serum interleukin-6(IL-6) and interleukin-17(IL-17) were decreased when compared with those before treatment(P<0.05);the levels of plasma MLT and serum GAS in the treatment group were higher than those in the control group(P<0.05),and the levels of serum IL-6 and IL-17 were lower than those in the control group(P<0.

关 键 词：慢性胃炎 反流性食管炎 脾虚气滞证 养胃颗粒 雷贝拉唑钠肠溶片 中医证候 胃肠激素 炎症因子 

分 类 号：R573.3[医药卫生—消化系统] R571[医药卫生—内科学]